Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023)

Aclaris Therapeutics' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $367000.0 for Q3 2023.

• In Q3 2023, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $367000.0; the TTM figure through Sep 2023 stood at $367000.0 (changed 0.0% YoY), while the FY2022 annual figure was $367000.0, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was $367000.0 for Q3 2023 at Aclaris Therapeutics, roughly flat from $367000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $549000.0 in Q1 2019 to a low of $367000.0 in Q4 2020.
• Historically, Non-Current Deferred Tax Liability has averaged $434052.6 across 5 years, with a median of $367000.0 in 2020.
• The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability changed 0.0% in 2019, then slumped 33.15% in 2020.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $549000.0 in 2019, then plunged by 33.15% to $367000.0 in 2020, then changed by 0.0% to $367000.0 in 2021, then changed by 0.0% to $367000.0 in 2022, then changed by 0.0% to $367000.0 in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $367000.0 (Q3 2023), $367000.0 (Q2 2023), and $367000.0 (Q1 2023), per Business Quant data.